Pharmacological Profile and Clinical Utility of Lamotrigine in Bipolar Disorders

Bipolar Psychopharmacotherapy: Caring for the Patient

Volumn , Issue , 2006, Pages 43-62

  Muzina, David J ^a   Calabrese, Joseph R ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Acute mood disturbances; Antiepileptic drug; Lamotrigine in bipolar disorders; Lamotrigine monotherapy; Lamotrigine associated rash; Mania rating scale; Pharmacokinetics; Prevention of mood disturbances

Indexed keywords

EID: 33749024903     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470017953.ch4     Document Type: Chapter

References (63)

1. Anderson, G. D., Yau, M. K., Gidal, B. E., Harris, S. J., Levy, R. H., Lai, A. A., Wolf, K. B., Wargin, W. A. and Dren, A. T. (1996). Bidirectional interaction of valproate and lamotrigine in healthy subjects, Clin Pharmacol Ther, 60, 145-56.
2. Barbosa, L., Berk, M. and Vorster, M. (2003). A double-blind, randomized, placebocontrolled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes, J Clin Psychiatry, 64, 403-407.
3. Bowden, C. L. (2003). Acute and maintenance treatment with mood stabilizers, Int J Neuropsychopharmacol, 6, 269-75.
4. Bowden, C. L., Calabrese, J. R., Sachs, G., Yatham, L. N., Asghar, S. A., Hompland, M., Montgomery, P., Earl, N., Smoot, T. M. and DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder, Arch Gen Psychiatry, 60, 392-400.
5. Calabrese J. R., Muzina D. J. How to treat bipolar II depression and bipolar II mixed depression? A reply to Benazzi, Int J Neuropsychopharmacol, Mar. 7 (1-2), 2004.
6. Calabrese, J. R., Fatemi, S. H. and Woyshville, M. J. (1996). Antidepressant effects of lamotrigine in rapid cycling bipolar disorder, Am J Psychiatry, 153, 1236.
7. Calabrese, J. R., Vieta, E. and Shelton, M. D. (2003). Latest maintenance data on lamotrigine in bipolar disorder, Eur Neuropsychopharmacol, 13, Suppl. 2, S57-66.
8. Calabrese, J. R., Bowden, C. L., McElroy, S. L., Cookson, J., Andersen, J., Keck, P. E., Jr., Rhodes, L., Bolden-Watson, C., Zhou, J. and Ascher, J. A. (1999a). Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder, Am J Psychiatry, 156, 1019-23.
9. Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E. and Rudd, G. D. (1999b). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group, J Clin Psychiatry, 60, 79-88.
10. Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L. and Monaghan, E. T. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group, J Clin Psychiatry, 61, 841-50.
11. Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.P., Montgomery, P., Ascher, J., Paska, W., Earl, N. and DeVeaugh-Geiss, J. (2003a). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder, J Clin Psychiatry, 64, 1013-24.
12. Calabrese, J. R., Hirschfeld, R. M., Reed, M., Davies, M. A., Frye, M. A., Keck, P. E., Lewis, L., McElroy, S. L., McNulty, J. P. and Wagner, K. D. (2003b). Impact of bipolar disorder on a U.S. community sample, J Clin Psychiatry, 64, 425-32.
13. Calabrese, J. R., Sullivan, J. R., Bowden, C. L., Suppes, T., Goldberg, J. F., Sachs, G. S., Shelton, M. D., Goodwin, F. K., Frye, M. A. and Kusumakar, V. (2002). Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management, J Clin Psychiatry, 63, 1012-19.
14. Chen, C., Veronese, L. and Yin, Y. (2000). The effects of lamotrigine on the pharmacokinetics of lithium, Br J Clin Pharmacol, 50, 193-5.
15. Choi, H. and Morrell, M. J. (2003). Review of lamotrigine and its clinical applications in epilepsy, Expert Opin Pharmacother, 4, 243-51.
16. Cohen, A. F., Ashby, L., Crowley, D., Land, G., Peck, A. W. and Miller, A. A. (1985). Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam, Br J Clin Pharmacol, 20, 619-29.
17. Cohen, A. F., Land, G. S., Breimer, D. D., Yuen, W. C., Winton, C. and Peck, A. W. (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans, Clin Pharmacol Ther, 42, 535-41.
18. Crawford, P. (2002). Interactions between antiepileptic drugs and hormonal contraception, CNS Drugs, 16(4), 263-272.
19. Cunnington, M., Tennis, P. and the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. (2005). Neurology, 64, 955-960.
20. Fitton, A. and Goa, K. L. (1995). Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy, Drugs, 50, 691-713.
21. Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Cora-Ocatelli, G., Leverich, G. S. and Post, R. M. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders, J Clin Psychopharmacol, 20, 607-14.
22. Garnett, W. R. (1997). Lamotrigine: Pharmacokinetics, J Child Neurol, 12, Suppl. 1, S10-15.
23. Gilman, J. T. (1995). Lamotrigine: An antiepileptic agent for the treatment of partial seizures, Ann Pharmacother, 29, 144-51.
24. Ginsberg, L., Sachs, G. and Ketter, T. (2003). In American Psychiatric Association 2003 Annual Meeting, San Francisco, CA, pp. 173-4.
25. Goa, K. L., Ross, S. R. and Chrisp, P. (1993). Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy, Drugs, 46, 152-76.
26. Goldsmith, D. R., Wagstaff, A. J., Ibbotson, T. and Perry, C. M. (2003). Lamotrigine: A review of its use in bipolar disorder, Drugs, 63, 2029-50.
27. Goodwin, G. M. (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology, J Psychopharmacol, 17, 149-73; discussion 147.
28. Goodwin, G. M., Bowden, C. L., Calabrese, J. R., Grunze, H., Kasper, S., White, R., Greene, P. and Leadbetter, R. (2004). A pooled analysis of two placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry, 65(3), 432-41.
29. Hachad, H., Ragueneau-Majlessi, I. and Levy, R. H. (2002). New antiepileptic drugs: review on drug interactions, Ther Drug Monit, 24, 91-103.
30. Hirschfeld, R. M., Calabrese, J. R., Weissman, M. M., Reed, M., Davies, M. A., Frye, M.A., Keck, P. E., Jr., Lewis, L., McElroy, S. L., McNulty, J. P. and Wagner, K. D. (2003). Screening for bipolar disorder in the community, J Clin Psychiatry, 64, 53-9.
31. Ichim, L., Berk, M. and Brook, S. (2000). Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial, Ann Clin Psychiatry, 12, 5-10.
32. Jacoby, A., Baker, G. A., Steen, N., Potts, P. and Chadwick, D. W. (1996). The clinical course of epilepsy and its psychosocial correlates: Findings from a U.K. community study, Epilepsia, 37(2), 148-161.
33. Judd, L. L. and Akiskal, H. S. (2003). The prevalence and disability of bipolar spectrum disorders in the U.S. population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord, 73, 123-131.
34. Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A. and Keller, M. B. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder, Arch Gen Psychiatry, 59, 530-7.
35. Kusumakar, V. and Yatham, L. N. (1997). An open study of lamotrigine in refractory bipolar depression, Psychiatry Res, 72, 145-8.
36. Leach, M. J., Marden, C. M. and Miller, A. A. (1986). Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action, Epilepsia, 27, 490-7.
37. Leach, M. J., Baxter, M. G. and Critchley, M. A. (1991). Neurochemical and behavioral aspects of lamotrigine, Epilepsia, 32, Suppl. 2, S4-8.
38. Li, X., Ketter, T. A. and Frye, M. A. (2002). Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?, J Affect Disord, 69, 1-14.
39. Matsuo, F., Bergen, D., Faught, E., Messenheimer, J. A., Dren, A. T., Rudd, G. D. and Lineberry, C. G. (1993). Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizure. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group, Neurology, 43, 2284-91.
40. Messenheimer, J. A. (2002). In: American Academy of Neurology Annual Meeting, Denver, CO.
41. Mikati, M. A., Schachter, S. C., Schomer, D. L., Keally, M., Osborne-Shafer, P., Seaman, C. A., Sheridan, P. H., Ashworth, M., Kupferberg, H., Valakas, A., etal. (1989). Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures, Clin Neuropharmacol, 12, 312-21.
42. Muzina, D. J. and Calabrese, J. R. (2003). Recent placebo-controlled acute trials in bipolar depression: focus on methodology, Int J Neuropsychopharmacol, 6, 285-91.
43. Muzina, D. J., El-Sayegh, S. and Calabrese, J. R. (2002). Antiepileptic drugs in psychiatry-focus on randomized controlled trial, Epilepsy Res, 50, 195-202.
44. Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H. and Walden, J. (2002). Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, doubleblind study, J Clin Psychiatry, 63, 337-44.
45. Ohman, I., Vitols, S. and Tomson, T. (2000). Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation, Epilepsia, 41, 709-13.
46. Pennell, P. B. (2003). Antiepileptic drug pharmacokinetics during pregnancy and lactation, Neurology, 61, S35-42.
47. Post, R. M., Denicoff, K. D., Leverich, G. S. Altshuler, L. L., Frye, M. A., Suppes, T. M., Keck, P. E., McElroy, S. L., Kupka, R., Nolen, W. A., Grunze, H. and Walden, J. (2002). Presentations of depression in bipolar illness, Clin Neurosci Res, 2, 142-57.
48. Rambeck, B. and Wolf, P. (1993). Lamotrigine clinical pharmacokinetics, Clin Pharmacokinet, 25, 433-43.
49. Ramsay, R. E., Pellock, J. M., Garnett, W. R., Sanchez, R. M., Valakas, A. M., Wargin, W. A., Lai, A. A., Hubbell, J., Chern, W. H., Allsup, T. et al. (1991). Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy, Epilepsy Res, 10, 191-200.
50. Rzany, B., Mockenhaupt, M., Baur, S., Schroder, W., Stocker, U., Mueller, J., Hollander, N., Bruppacher, R. and Schopf, E. (1996). Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry, J Clin Epidemiol, 49, 769-73.
51. Sabers, A., Buchholt, J., Uldall, P. and Hansen, E. (2001). Lamotrigine plasma levels reduced by oral contraceptives, Epilepsy Res, 47, 151-4.
52. Shiah, I. S., Yatham, L. N., Lam, R. W. and Zis, A. P. (1998). Effects of lamotrigine on the 5-HT1A receptor function in healthy human males, J Affect Disord, 49, 157-62.
53. Smith, D., Baker, G., Davies, G., Dewey, M. and Chadwick, D. W. (1993a). Outcomes of add-on treatment with lamotrigine in partial epilepsy, Epilepsia, 34, 312-22.
54. Smith, D., Chadwick, D., Baker, G., Davis, G. and Dewey, M. (1993b). Seizure severity and the quality of life, Epilepsia, 34, Suppl. 5, S31-5.
55. Tran, T. A., Leppik, I. E., Blesi, K., Sathanandan, S. T. and Remmel, R. (2002). Lamotrigine clearance during pregnancy, Neurology, 59, 251-5.
56. Vinod, K. Y. and Subhash, M. N. (2002). Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain, Neurochem Int, 40, 315-9.
57. Walden, J., Hesslinger, B., van Calker, D. and Berger, M. (1996). Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder, Pharmacopsychiatry, 29, 193-5.
58. Weisler, R., Risner, M., Ascher, J. and Houser, T. (1994). In: American Psychiatric Association 1994 Annual Meeting, Philadelphia, PA.
59. Weissman, M. M., Bland, R. C., Canino, G. J., Faravelli, C., Greenwald, S., Hwu, H. G., Joyce, P. R., Karam, E. G., Lee, C. K., Lellouch, J., Lepine, J. P., Newman, S. C., Rubio-Stipec, M., Wells, J. E., Wickramaratne, P. J., Wittchen, H. and Yeh, E. K. (1996). Cross-national epidemiology of major depression and bipolar disorder, JAMA, 276, 293-9.
60. Wong, I. C., Mawer, G. E. and Sander, J. W. (1999). Factors influencing the incidence of lamotrigine-related skin rash, Ann Pharmacother, 33, 1037-42.
61. Xie, X. and Hagan, R. M. (1998). Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder, Neuropsychobiology, 38, 119-30.
62. Xie, X., Lancaster, B., Peakman, T. and Garthwaite, J. (1995). Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na + channels and with native Na + channels in rat hippocampal neurones, Pflugers Arch, 430, 437-46.
63. Yuen, A. W., Land, G., Weatherley, B. C. and Peck, A. W. (1992). Sodium valproate acutely inhibits lamotrigine metabolism, Br J Clin Pharmacol, 33, 511-3.